Hexarelin vs MK-677
Both stimulate GH release through the ghrelin receptor, but Hexarelin is an injectable hexapeptide while MK-677 is an orally active non-peptide compound. MK-677 offers convenience; Hexarelin offers stronger acute GH pulses.
Last updated: 2026-03-08
Hexarelin and MK-677 (Ibutamoren) are both growth hormone secretagogues that act on the ghrelin/GHS receptor to stimulate pituitary GH release. However, they represent fundamentally different molecular approaches — Hexarelin is a synthetic hexapeptide requiring injection, while MK-677 is a non-peptide, orally bioavailable compound.
Hexarelin (Examorelin) was developed as one of the first potent GHS-R agonists and produces strong, acute GH pulses. It was extensively studied in the 1990s-2000s for cardiac and endocrine applications.
MK-677 (Ibutamoren mesylate) was developed by Merck as an orally active GH secretagogue, offering the convenience of oral dosing with sustained 24-hour GH elevation. It has been studied for muscle wasting, osteoporosis, and age-related GH decline.
**Important Note:** Neither Hexarelin nor MK-677 is approved for therapeutic use by the MHRA, EMA, or FDA. This comparison is for educational purposes.
Quick Comparison Table
| Category | Hexarelin | MK-677 |
|---|---|---|
| Chemical Class | Synthetic hexapeptide (6 amino acids) | Non-peptide benzolactam (small molecule) |
| Administration | Subcutaneous or IV injection only | Oral (capsule/liquid) — key advantage |
| GH Release Pattern | Strong acute pulse (rapid onset, shorter duration) | Sustained 24-hour GH/IGF-1 elevation |
| Half-Life | ~70 minutes | ~4-6 hours (effects last 24 hours) |
| Cortisol/Prolactin | Elevates both cortisol and prolactin at higher doses | Mild cortisol increase; minimal prolactin effect |
| Appetite Effect | Moderate appetite stimulation | Significant appetite stimulation (ghrelin-like) |
| Desensitisation | Significant — GH response diminishes with chronic use | Minimal — sustained efficacy over months |
| Regulatory Status (UK) | Research compound only | Research compound only; WADA prohibited |
How They Work: Mechanism of Action
Hexarelin
Hexarelin Mechanism:
Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide and one of the most potent GHS-R agonists:
1. **GHS-R1a Full Agonism** Hexarelin is a strong full agonist at the ghrelin receptor, producing robust, rapid GH release from pituitary somatotrophs. The GH pulse is typically higher than that produced by Ipamorelin or GHRP-2/6.
2. **Broad Hormonal Effects** Unlike more selective GHS compounds, Hexarelin also stimulates cortisol, prolactin, and ACTH release at higher doses. This broader activity limits its long-term appeal but reflects strong receptor engagement.
3. **Cardiac Effects** Hexarelin has unique cardioprotective properties independent of GH release. It binds to a distinct cardiac receptor (CD36/scavenger receptor) and has shown anti-ischaemic effects, reduced infarct size, and improved cardiac function in preclinical and clinical studies.
4. **Receptor Desensitisation** A significant limitation: chronic Hexarelin use leads to GHS receptor desensitisation. GH response diminishes markedly after 4-8 weeks of continuous use, requiring cycling or breaks.
5. **Acute Potency** For single-dose GH stimulation, Hexarelin produces among the highest GH peaks of any secretagogue — useful for diagnostic or acute research applications.
MK-677
MK-677 (Ibutamoren) Mechanism:
MK-677 is a non-peptide spiropiperidine that mimics ghrelin's action without being a peptide:
1. **Oral GHS-R1a Agonism** MK-677 is orally bioavailable — it survives gastric digestion and first-pass liver metabolism. This is its primary advantage over peptide GH secretagogues.
2. **Sustained GH Elevation** Unlike the acute pulse from Hexarelin, MK-677 produces sustained 24-hour elevation of GH and IGF-1 levels from a single daily oral dose. This more closely mimics youthful GH patterns.
3. **IGF-1 Elevation** MK-677 reliably increases IGF-1 levels by 40-89% in clinical studies, sustained over months of use without significant desensitisation.
4. **Ghrelin-Like Effects** As a ghrelin mimetic, MK-677 stimulates appetite, can increase body weight, and may affect sleep architecture. These are side effects for some but therapeutic targets for others (e.g., muscle wasting, cachexia).
5. **Minimal Desensitisation** Unlike Hexarelin, MK-677 maintains its GH-releasing efficacy over extended periods. Studies of up to 2 years show sustained IGF-1 elevation, making it suitable for chronic use research.
Clinical Trial Evidence
Hexarelin Clinical Studies
Design: Randomised controlled trial
Participants: 7 participants
Ghrelin shows no interaction with HEX, whereas it has a synergistical effect with GHRH on GH secretion. Thus, ghrelin is a new hormone playing a major role in the control of somatotroph secretion in humans, and its effects are imitated by nonnatural GHS.
View study — PubMed 11238504Design: Randomised controlled trial
These data suggest that either the hexarelin or desmopressin test can be used to differentiate patients with Cushing's disease from subjects with alcohol-dependent pseudo-Cushing's syndrome.
View study — PubMed 10886488Design: Randomised controlled trial
In conclusion, the present results demonstrate that in humans Tyr-Ala-HEX is a GH secretagogue as potent as HEX and GHRP-2, two GHRP-6 superanalogs. Tyr-Ala-HEX also shares with HEX and GHRP-2 the same PRL- ACTH- and cortisol-releasing activity.
View study — PubMed 10195374Design: Randomised controlled trial
These findings suggest that in man, the acute administration of Hexarelin exerts a short-lasting, positive inotropic effect. This effect seems GH-independent and might be mediated by specific GHS myocardial receptors.
View study — PubMed 10342360MK-677 Clinical Studies
Design: Randomised controlled trial
Participants: 416 participants
Duration: 12 months
Despite evidence of target engagement as indicated by an increase in serum insulin-like growth factor-1, the human growth hormone secretagogue MK-677 25 mg was ineffective at slowing the rate of progression of Alzheimer disease.
View study — PubMed 19015485Design: Randomised controlled trial
The proportion of 20K GH in 2-h samples after the initial MK-677 administration was lower than that after 2 and 8 weeks. These moderate changes in the proportion non-22K GH isoforms are likely of small importance for the clinical response to MK-677 treatment.
View study — PubMed 12550076Design: Randomised controlled trial
Participants: 292 participants
Duration: 12 months
In conclusion, the anabolic effect of GH, as produced through the GH secretagogue MK-677, attenuated the indirect suppressive effect of alendronate on bone formation, but did not translate into significant increases in BMD at sites other than the femoral neck.
View study — PubMed 11238495Design: Randomised controlled trial
Participants: 12 participants
Duration: 8 weeks
At study end, the LDL-C/HDL-C ratio was decreased. MK-677 treatment did not significantly affect serum Lp(a) concentrations at the present dose and administration protocol.
View study — PubMed 10372705Benefits Comparison
Hexarelin Unique Benefits
- Produces the strongest acute GH pulse of any peptide GHS
- Unique cardioprotective effects via CD36 receptor (independent of GH)
- Useful as a diagnostic GH stimulation tool
- More precise dosing control via injection
- Less appetite stimulation than MK-677
- Does not affect blood glucose as significantly
Shared Benefits
- Stimulate endogenous GH release via ghrelin receptor pathway
- Increase IGF-1 levels through natural GH-IGF-1 axis
- Do not suppress natural GH production
- Potential body composition improvement (lean mass, fat reduction)
- Generally well-tolerated in research settings
MK-677 Unique Benefits
- Orally bioavailable — no injections required
- Sustained 24-hour GH/IGF-1 elevation from single daily dose
- Minimal receptor desensitisation — effective over months/years
- Extensive long-term human data (up to 2 years)
- Improves bone mineral density in clinical trials
- Enhances deep sleep and REM sleep architecture
- Anti-catabolic — preserves muscle during caloric restriction
- Largest clinical dataset of any non-approved GH secretagogue
Research & Evidence
Hexarelin Research
Hexarelin Research Evidence:
Hexarelin research peaked in the late 1990s-early 2000s, with particular focus on its potency and cardiac effects.
Key Research Areas:
GH Release Potency - Highest acute GH release of any peptide secretagogue - 2-3x more potent than GHRP-6 per milligram - Strong dose-response relationship
Cardioprotection - Unique binding to cardiac CD36 receptor - Improved cardiac function in heart failure patients - Anti-ischaemic effects independent of GH release
Limitations: - Significant receptor desensitisation with chronic use (4-8 weeks) - Elevates cortisol and prolactin at higher doses - Research activity declined after desensitisation findings - No pharmaceutical development beyond Phase II
MK-677 Research
MK-677 (Ibutamoren) Research Evidence:
MK-677 has the most extensive clinical dataset of any non-approved GH secretagogue, with studies up to 2 years.
Key Research Areas:
Ageing and Body Composition - 2-year study in elderly showed sustained IGF-1 elevation and improved lean mass - No desensitisation over extended use - Potential for age-related GH decline
Bone Health - Phase II trial in 292 post-menopausal women - Improved bone mineral density at femoral neck - Anti-fracture potential in osteoporosis
Muscle Preservation - Reversed nitrogen wasting during caloric restriction - Potential for cachexia, sarcopenia, and surgical recovery
Sleep - Improved deep sleep (stage IV) by 50% and REM by 20%
Limitations: - Appetite stimulation can cause unwanted weight gain - Potential insulin resistance with long-term use - Fluid retention and joint pain reported - Has not progressed to Phase III for any indication
Head-to-Head Analysis
Direct Comparison:
No head-to-head trial has compared Hexarelin and MK-677 directly.
Key Differentiator — Desensitisation: The most important practical difference is desensitisation. Hexarelin's GH-releasing effect diminishes significantly after 4-8 weeks of continuous use, requiring cycling. MK-677 maintains efficacy for months to years with no significant attenuation.
Administration: MK-677's oral bioavailability is a major practical advantage for chronic use research. Hexarelin requires injection.
GH Release Pattern: Hexarelin produces higher acute GH peaks; MK-677 produces more sustained GH/IGF-1 elevation. The clinical significance of acute vs sustained patterns remains debated.
Unique Properties: Hexarelin's cardioprotective effects via CD36 are unique and not shared by MK-677. MK-677's bone density effects have been studied more extensively.
Protocol Comparison
Hexarelin Protocol
Hexarelin Theoretical Protocols (Research-Based):
Dosing: Clinical studies used 1-2 mcg/kg IV or SC. Common research doses cited: 100-200 mcg SC, 1-3 times daily.
Routes: - Subcutaneous injection - Intravenous (clinical/diagnostic settings)
Duration: Due to desensitisation, Hexarelin is typically discussed in cycles of 4-8 weeks on, followed by 4-8 weeks off.
Key Consideration: Desensitisation is the primary protocol concern. GH response may drop by 50-80% after 8 weeks of continuous use.
⚠️ Disclaimer: No approved therapeutic protocols exist for Hexarelin.
MK-677 Protocol
MK-677 Theoretical Protocols (Research-Based):
Dosing: Clinical trials used 10-25mg orally once daily. 25mg/day is the most studied dose.
Routes: - Oral (capsule or liquid) — single daily dose
Duration: Studies have run up to 2 years without desensitisation. Long-term continuous use is feasible from an efficacy standpoint.
Key Consideration: Appetite stimulation and potential insulin resistance with long-term use are the primary concerns. Fasting glucose and HbA1c monitoring is discussed in research contexts.
⚠️ Disclaimer: No approved therapeutic protocols exist for MK-677.
Combined Use
Theoretical Combined Use:
Combining Hexarelin and MK-677 is generally not recommended as both act on the same ghrelin receptor.
Rationale Against: - Both are GHS-R agonists — receptor competition rather than synergy - Would likely amplify side effects (cortisol, appetite) without proportional GH benefit - No research supports this combination
Better Alternatives: - MK-677 + GHRH analogue (e.g., CJC-1295) — different receptor targets, proven synergy - Hexarelin + GHRH analogue — same synergy principle during Hexarelin's effective window
⚠️ Combining two GHS-R agonists has no scientific basis.
Safety Profiles
Hexarelin Safety
Hexarelin Safety Profile:
Clinical Data: - Well-tolerated at clinical doses in short-term studies - Significant cortisol elevation at higher doses (dose-limiting) - Prolactin elevation reported (less than GHRP-2)
Key Safety Concerns: - Cortisol elevation can be clinically significant at high doses - Desensitisation requires cycling, complicating long-term use - Broader hormonal effects than more selective GHS compounds
Side Effects: - Flushing and warmth at injection site - Increased appetite - Water retention - Headache - Dizziness (rare)
Regulatory: Research compound only. Not approved for human therapeutic use. WADA prohibited.
MK-677 Safety
MK-677 Safety Profile:
Clinical Data (up to 2 years): - Generally well-tolerated in studies up to 2 years - Main concerns: appetite stimulation, fluid retention, potential insulin resistance
Key Safety Concerns: - Fasting glucose may increase with long-term use (insulin resistance) - Significant appetite stimulation can lead to unwanted weight gain - Oedema and joint pain from water retention - May exacerbate pre-existing diabetes or glucose intolerance
Side Effects: - Increased appetite (very common — ghrelin effect) - Water retention/bloating - Lethargy/drowsiness (especially early use) - Muscle/joint pain - Transient increase in fasting glucose
Regulatory: Research compound only. Not approved by MHRA, EMA, or FDA. WADA prohibited. Has been sold as a "research chemical" in grey markets.
The Verdict: When to Choose Which?
Choose Hexarelin When:
- When studying acute GH pulse responses or GH diagnostic testing
- When cardiac protection research is a primary interest (CD36 pathway)
- When short-term GH stimulation studies require the most potent secretagogue
- When appetite stimulation and metabolic effects need to be minimised
- When studying GHS receptor desensitisation mechanisms
Choose MK-677 When:
- When oral administration is essential (no injection capability)
- When sustained, long-term GH/IGF-1 elevation is the research goal
- When studying bone density, muscle preservation, or age-related GH decline
- When sleep quality improvement is a research outcome
- When studying anti-catabolic effects during caloric restriction
- When long-term compliance and convenience are priorities
Consider Combining When:
- Combination is generally not recommended — both target the same GHS receptor
- Would likely produce receptor competition and amplified side effects
- Better to pair either with a GHRH analogue for true receptor-level synergy
- No research supports combining two GHS-R agonists
Frequently Asked Questions
Conclusion
Hexarelin and MK-677 represent two distinct approaches to ghrelin-receptor-mediated GH stimulation. Hexarelin offers the most potent acute GH pulses of any peptide secretagogue and unique cardioprotective properties, but is limited by injection requirement and significant receptor desensitisation. MK-677 offers oral convenience, sustained GH/IGF-1 elevation, minimal desensitisation, and the most extensive long-term clinical data of any non-approved GH secretagogue. For chronic GH elevation research, MK-677 is more practical. For acute GH studies or cardiac research, Hexarelin offers unique advantages. Neither should be combined with the other, as both target the same receptor system.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Hexarelin nor MK-677 is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.